menu

A Guide to Evolving Treatment of nAMD and DME Using Real-World Data

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data

4 chapters
Play All
1.00 credits
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.

  • Target Audience

    This activity has been designed to address the educational needs of retina specialists and comprehensive ophthalmologists. It may also benefit other clinicians involved in the care of patients with neovascular retinal diseases. 

  • Provider(s)/Educational Partner(s)

    This activity is provided by Paradigm Medical Communications, LLC.   

     

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.   

  • Learning Objectives

    Upon completion of this activity, participants should be able to: 

    • Describe the limitations of anti-VEGF therapy that have been illuminated by real-world analyses 

    • Evaluate real-world data demonstrating optimal use of dual inhibition therapy, including patient selection and dosing intervals 

    • Formulate treatment plans for patients with nAMD and DME that demonstrate appropriate integration and ongoing use of dual inhibition therapy, based on real-world evidence 

  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement  
    Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physician Credit Designation Statement 

    Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    PA Continuing Education  

    PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Creditfrom organizations accredited by ACCME or a recognized state medical society. 

    Nurse Practitioner Continuing Education  

    The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines. 

  • Instructions for Participation

    To receive a certificate of participation, participants must: 

    • Follow instructions to register or log in with your professional information and complete the preassessment 

    • View the online activity in its entirety 

    • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment 

    A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation. 
     
    For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com. 

    There are no fees for participating in this activity.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. 

    All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

    The content of this activity was independentlyreviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

    Arshad M. Khanani, MD, MA, FASRS 

    Consultant: 4D Molecular Therapeutics; AbbVie Inc; Adverum Biotechnologies, Inc; Alcon; Amgen Inc; Annexin Pharmaceuticals; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Beacon Therapeutics; Clearside BioMedical; Complement Therapeutics Ltd; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc.; Genentech, Inc; Gyroscope Therapeutics Limited; i-Lumen Scientific; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Kriya Therapeutics; Nanoscope Therapeutics, Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocuphire Pharma, Inc; OcuTerra Therapeutics; Olive BioPharma; Opthea; Oxular; Oxurion NV; Perfuse Therapeutics; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Revive Therapeutics; RevOpsis Therapeutics LLC; Sanofi; Stealth BioTherapeutics Inc; Thea Pharma Inc; UNITY Biotechnology; Vanotech; Vial 

    Speaker’s Bureau: IVERIC bio, Inc 

    Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Neurotech Pharmaceuticals, Inc; Ocular Therapeutix; Oculis; OcuTerra Therapeutics; Opthea; Oxular; Oxurion NV; REGENXBIO Inc; Vanotech; UNITY Biotechnology 

    Stocks: Aviceda Therapeutics; Oculis; Opthea; Perfuse Therapeutics; PolyPhotonix Medical Ltd; RecensMedical, Inc; RevOpsis Therapeutics; Vial 

    Theodore Leng, MD, MS 

    Advisor: Apellis Pharmaceuticals, Inc; Astellas Pharma US, Inc; Boehringer Ingelheim International GmbH; Nanoscope Therapeutics, Inc; Regeneron Pharmaceuticals Inc 

    Consultant: Alcon; F. Hoffmann-La Roche Ltd 

    Research Funding: Astellas Pharma US, Inc 

    Peer Reviewer 

    Stock: F. Hoffmann-La Roche Ltd (expired 3/24); Medtronic (expired 3/24); Pfizer Inc. (expired 3/24) 

    Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies todisclose. 

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. 

  • Terms of Use

    Disclaimer 

    The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity. 

  • Disclaimer

    This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. 

    If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. 

    As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.

  • Target Audience

    This activity has been designed to address the educational needs of retina specialists and comprehensive ophthalmologists. It may also benefit other clinicians involved in the care of patients with neovascular retinal diseases. 

  • Provider(s)/Educational Partner(s)

    This activity is provided by Paradigm Medical Communications, LLC.   

     

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.   

  • Learning Objectives

    Upon completion of this activity, participants should be able to: 

    • Describe the limitations of anti-VEGF therapy that have been illuminated by real-world analyses 

    • Evaluate real-world data demonstrating optimal use of dual inhibition therapy, including patient selection and dosing intervals 

    • Formulate treatment plans for patients with nAMD and DME that demonstrate appropriate integration and ongoing use of dual inhibition therapy, based on real-world evidence 

  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement  
    Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physician Credit Designation Statement 

    Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    PA Continuing Education  

    PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Creditfrom organizations accredited by ACCME or a recognized state medical society. 

    Nurse Practitioner Continuing Education  

    The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines. 

  • Instructions for Participation

    To receive a certificate of participation, participants must: 

    • Follow instructions to register or log in with your professional information and complete the preassessment 

    • View the online activity in its entirety 

    • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment 

    A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation. 
     
    For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com. 

    There are no fees for participating in this activity.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. 

    All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

    The content of this activity was independentlyreviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

    Arshad M. Khanani, MD, MA, FASRS 

    Consultant: 4D Molecular Therapeutics; AbbVie Inc; Adverum Biotechnologies, Inc; Alcon; Amgen Inc; Annexin Pharmaceuticals; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Beacon Therapeutics; Clearside BioMedical; Complement Therapeutics Ltd; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc.; Genentech, Inc; Gyroscope Therapeutics Limited; i-Lumen Scientific; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Kriya Therapeutics; Nanoscope Therapeutics, Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocuphire Pharma, Inc; OcuTerra Therapeutics; Olive BioPharma; Opthea; Oxular; Oxurion NV; Perfuse Therapeutics; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Revive Therapeutics; RevOpsis Therapeutics LLC; Sanofi; Stealth BioTherapeutics Inc; Thea Pharma Inc; UNITY Biotechnology; Vanotech; Vial 

    Speaker’s Bureau: IVERIC bio, Inc 

    Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Neurotech Pharmaceuticals, Inc; Ocular Therapeutix; Oculis; OcuTerra Therapeutics; Opthea; Oxular; Oxurion NV; REGENXBIO Inc; Vanotech; UNITY Biotechnology 

    Stocks: Aviceda Therapeutics; Oculis; Opthea; Perfuse Therapeutics; PolyPhotonix Medical Ltd; RecensMedical, Inc; RevOpsis Therapeutics; Vial 

    Theodore Leng, MD, MS 

    Advisor: Apellis Pharmaceuticals, Inc; Astellas Pharma US, Inc; Boehringer Ingelheim International GmbH; Nanoscope Therapeutics, Inc; Regeneron Pharmaceuticals Inc 

    Consultant: Alcon; F. Hoffmann-La Roche Ltd 

    Research Funding: Astellas Pharma US, Inc 

    Peer Reviewer 

    Stock: F. Hoffmann-La Roche Ltd (expired 3/24); Medtronic (expired 3/24); Pfizer Inc. (expired 3/24) 

    Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies todisclose. 

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. 

  • Terms of Use

    Disclaimer 

    The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity. 

  • Disclaimer

    This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. 

    If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. 

    As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule24 May 2024